RFA-CA-24-024: Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 31, 2024.
From the official notice on Grants.gov, last changed August 12, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG1
- Clinical trialsRequired
- Funded byNCI
- Median yearly award$1.5 million
- Typical project length12 years
Projects funded under RFA-CA-24-024 were run by National Cancer Institute (NCI, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-24-024 in the NIH Guide.
Key dates
| Posted | August 12, 2024 |
|---|---|
| Deadline | October 31, 2024 |
| Archived by Grants.gov | December 6, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (60% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to provide the infrastructure for early-phase cancer prevention clinical trials through the Cancer Prevention Clinical Trials Network (CP-CTNet), DCP's main mechanism for early clinical development of cancer preventive interventions. The phase 0-2 trials performed through CP-CTNet evaluate biologic effects of interventions and determine clinically relevant correlates, with the ultimate goal of advancing their further development for cancer prevention. The research network will develop multiple cancer prevention clinical trials targeting cancers arising in various organ sites, including collaborative studies across the Network, using the UG1 cooperative agreement funding mechanisms. This NOFO relates to the performance sites that will plan and perform clinical trials.
Funded under RFA-CA-24-024 so far
NIH funded 4 projects under RFA-CA-24-024 in fiscal 2025 to 2026, at 4 institutions. The median yearly award was $1.5 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Early Phase Clinical Cancer Prevention Consortium | University of Michigan at Ann Arbor | 2026 | $1.4 million |
| iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium | University of TX MD Anderson Can Ctr | 2026 | $733,978 |
| University of Arizona Cancer Prevention Clinical Trials Network | University of Arizona | 2026 | $850,832 |
| Northwestern Cancer Prevention Consortium | Northwestern University | 2026 | $1.9 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Who has won Cancer Control grants before
From fiscal 2021 to 2025, Cancer Control (93.399) awarded $814 million across 113 grant awards, an average of $7.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Ecog-Acrin Medical Research Foundation, Inc. | Pennsylvania | 1 | $87.9 million |
| NRG Oncology Foundation Inc | Pennsylvania | 1 | $54.3 million |
| Alliance NCTN Foundation | Illinois | 1 | $50.2 million |
| Oregon Health & Science University | Oregon | 2 | $34.4 million |
| University of Rochester | New York | 1 | $29.8 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-24-024 still open?
No. It closed on October 31, 2024.
Who can apply for Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)?
Closed October 31, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-CA-24-024?
NIH RePORTER lists 4 projects funded under RFA-CA-24-024 in fiscal 2025 to 2026, at 4 institutions. The most were at University of Michigan at Ann Arbor, University of TX MD Anderson Can Ctr, University of Arizona.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)